References
- Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47(1):46–53.
- Viinikainen K, Heinonen S, Eriksson K, Kalviainen R. Community based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia. 2006;47(1):186–92.
- Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in women with epilepsy: population-based cohort study. BJOG. 2009;116(13):1736–42.
- Chen YH, Chiou HY, Lin HC, Lin HL. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol. 2009;66(8):979–84.
- Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, et al. Practice parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.
- Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1–13.
- Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia. 2008;49(9):43–55.
- Graves JC, Miller KE. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002;65(5):915–20.
- Dugoff L. First and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol. 2010;115(5):1052–61.
- Newberger DS. Down syndrome: prenatal risk assessment and diagnosis. Am Fam Physician. 2000;62(4):825–32.
- Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Gagnon A, Johnson JA, Langlois S, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. Obstet Gynaecol Can. 2008;30(10):918–49.
- Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, Johnson MP, Evans MI. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotrophin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181(4):968–74.
- D'Alton M, Cleary-Goldman J. First and second trimester evaluation of risk for fetal aneuploidy: the secondary outcomes of the FASTER trial. Semin Perinatol. 2005;29(4):240–46.
- Turkcapar F, Engin-Üstün Y, Simsek OY, Deveer R, Danisman N, Dilmen U, Mollamahmutoglu L. First and second trimester biochemical markers in familial mediterranean fever. Eur Rev Med Pharmacol Sci. 2013;17(13):1820–23.
- Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, et al. FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106(2):260–7.
- Siiteri PK, MacDonald PC. Placental estrogen biosynthesis during human pregnancy. J Clin Endocrinol. 1966;26(7):751–61.
- Olsen RN, Dunsmoor-Su R, Capurro D, Mcmahon K, Gravett MG. Correlation between spontaneous preterm birth and mid-trimester maternal serum estriol. J Matern Fetal Neonatal Med. 2014;27(4):376–80.
- Korebrits C, Ramirez MM, Watson L, Brinkman E, Bocking AD, Challis JR. Maternal corticotropin-releasing hormone is increased with impending preterm birth. J Clin Endocrinol Metab. 1998;83(5):1585–91.
- Wood CE. Development and programming of the hypothalamus-pituitary-adrenal axis. Clin Obstet Gynecol. 2013;56(3):610–21.
- Goodwin TM. A role for estriol in human labor, term and preterm. Am J Obstet Gynecol. 1999;180(1 Pt 3):208–13.
- Heine RP, McGregor JA, Goodwin TM, Artal R, Hayashi RH, Robertson PA, Varner MW. Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol. 2000;96(4):490–7.